CR Pharmaceutical Commercial opens RMB 5.5b equity raise as hospital rules shift cash cycles
China Resources Pharmaceutical (HKEX: 03320) launched CBEX bidding (G62026BJ1000075-0) on Nov 20, 2026 for CR Pharmaceutical Commercial to raise up to RMB 5.5b externally plus RMB 2b from Beijing Pharma.
China Resources Pharmaceutical Group Limited (HKEX: 03320) announced via an Inside Information filing on November 20, 2026 that its non-wholly-owned distribution flagship, CR Pharmaceutical Commercial Group Company Limited, formally opened public bidding on the China Beijing Equity Exchange (CBEX, Project G62026BJ1000075-0) to issue up to RMB 5.5 billion in new shares to no more than 15 external investors. In addition, wholly-owned subsidiary Beijing Pharmaceutical Group holds an option to concurrently subscribe for up to RMB 2.0 billion by non-public issuance at the identical external clearing price—putting total potential equity proceeds at up to RMB 7.5 billion to fund mergers and acquisitions (M&A), logistics infrastructure, and repayment of outstanding interest-bearing debt.
While headline announcements frame the transaction as routine growth capital following the October 16 pre-disclosure, cross-checking the CBEX filing against CITIC Securities’ June 2026 bond trustee report (24 Runyao 01 / 25 Runyao 05) reveals why China’s third-largest pharmaceutical wholesaler is raising up to RMB 7.5 billion in fresh equity now: public-hospital receivable cycles have stretched CR Pharmaceutical Commercial’s total liabilities to RMB 125.61 billion (75.55% asset-liability ratio) at the exact moment that provincial execution of the four-ministry Class 1 hospital formulary notice (Guoweiban Yizheng Fa [2026] No. 18) and NMPA electronic traceability pilots are shifting more working-capital burden onto Tier-1 national distributors.
A 6.44% hospital gross margin against RMB 125.61 billion in liabilities
Audited FY2025 bond disclosures for CR Pharmaceutical Commercial illustrate the razor-thin margin and working-capital mechanics of China’s public-hospital distribution model:
Financial & Cap-Table Metric (CR Pharmaceutical Commercial) |
FY2024 Audited | FY2025 Audited / Current (CBEX G62026BJ1000075-0) |
YoY Change / Structural Detail |
|---|---|---|---|
| Total Operating Revenue | RMB 213.20 billion |
RMB 221.00 billion (RMB 221,004 million) |
+3.66% YoY; overall gross margin 6.46% (-5 bps) |
Direct Hospital Sales (Yiliao Chunxiao) |
RMB 148.20 billion (69.51% share) |
RMB 151.42 billion (68.51% share) |
Gross margin 6.44% (+22 bps); core tertiary/secondary hospital supply |
Wholesale Distribution (Yiyao Fenxiao) & Retail |
Wholesale RMB 56.44b (6.45% GM); Retail RMB 7.74b (6.23% GM) |
Wholesale RMB 59.53b (5.77% GM); Retail RMB 9.14b (5.80% GM) |
Wholesale margin compressed -68 bps; retail revenue grew +18.07% (DTP expansion) |
Net Profit & EBITDA |
Net profit RMB 2.21b (EBITDA RMB 5.81b) |
Net profit RMB 2.39 billion (EBITDA RMB 5.94b) |
1.08% net margin; attributable net profit RMB 1.87 billion |
| Total Assets / Total Liabilities / Debt Ratio | Assets RMB 155.93b / Liabilities RMB 120.38b (77.20%) |
Assets RMB 166.24b / Liabilities RMB 125.61b (75.55%) |
Total debt / EBITDA 8.08x; financing cash outflow -RMB 8.75 billion |
| Accounts-Receivable & Inventory Turnover | AR turnover 3.22x (~113 days); Inventory 7.79x |
AR turnover 2.86x (~128 days); Inventory 6.71x |
AR turnover slowed -11.31% YoY; Interest coverage fell -12.19% (3.61x to 3.17x) |
Pre-Issuance Shareholder Register (CBEX filing) |
Post-2023 debt-to-equity (Zhaizhuangu) round |
CR Pharma (03320.HK) holds 80.13% (Beijing Pharma 71.05% + CR Pharma Inv. 9.08%) |
Big Five bank AICs hold 18.55% (ICBC, CCB, ABC, BOCOM at 3.78% each + BOC 3.44%), plus PICC 0.76% & Guorui 0.57% |
Because CR Pharmaceutical Commercial already brought in the financial asset investment (AIC) debt-to-equity arms of China’s Big Five state-owned banks (ICBC, CCB, ABC, BOCOM, and BOC) for a combined 18.55% stake during its prior capital round, launching a second CBEX equity raise of up to RMB 5.5 billion from external institutions (plus up to RMB 2.0 billion from Beijing Pharmaceutical Group to prevent parent control dilution) underscores how fast working-capital requirements are growing. Even if the full RMB 7.5 billion is raised and applied entirely against liabilities, pro-forma asset-liability leverage on its RMB 166.24 billion balance sheet would ease by roughly 3.3 percentage points to ~71%–72%.
Why hospital formulary loosening and digital traceability favor giant wholesalers
Two regulatory developments over the past ten days explain why CR Pharmaceutical Commercial is simultaneously earmarking proceeds for debt repayment, cold-chain/specialty logistics, and regional M&A:
- Hospital formulary loosening increases distributor working-capital intensity: Under the four-ministry notice (Circular on Further Improving the Safe and Rational Equipping and Use of Innovative Drugs,
Guoweiban Yizheng Fa [2026] No. 18, issued October 30 and republished for implementation by provincial health andNHSAbureaus in Xinjiang, Shaanxi, Shanghai, and Yunnan between November 11 and November 20), secondary and tertiary public hospitals must convene Pharmacy and Therapeutics (P&T) committees to stock Class 1 drugs from the 2026NRDLand the 28-drug Commercial Health Insurance Innovative Drug List, exempted fromone-drug-two-specifications(yipin lianggui) caps and per-visit drug-cost growth indicators. Because direct hospital sales (yiliao chunxiao) account for 68.51% ofCR Pharmaceutical Commercial’s revenue and carry an average collection cycle of ~128 days (2.86xannual turnover), onboarding high-unit-priceADCs, bispecifics, and rare-disease biologics into public hospitals requires distributors to finance months of upstream manufacturer payables before hospitals settle receivables. - One-click electronic circulation traceability squeezes small wholesalers into
M&A: In late September and October 2026, provincial drug regulators in Jiangxi (covering 20 pilot enterprises across 7 scenarios) and Henan (covering 16 pilot enterprises across 4 baseline scenarios) launched China’s firstone-click penetration(yijian chuantou) electronic drug-circulation supervision pilots—replacing paper batch-release certificates (yaojian baogao), shipping manifests (suihuo tongxing dan), and first-time vendor qualification dossiers (shouying ziliao) with real-time regulatory data feeds. While digital archiving lowers compliance friction for national wholesalers with integrated ERP infrastructure, regional distributors facing bothVBPprice compression and mandatory digital traceability upgrades are increasingly primeM&Atargets for cash-rich consolidators.
Next evidence triggers to watch
- Final
CBEXbidding close and subscription agreement (G62026BJ1000075-0, Q4 2026 – Q1 2027): Final subscribed amount against the RMB 5.5 billion external cap, the filed state-owned asset appraisal floor price, whetherBeijing Pharmaceutical Groupexercises its RMB 2.0 billion matching option, and the resulting post-money dilution ofCR Pharma’s (03320.HK)80.13%stake. - FY2026 bond report working-capital metrics (April–June 2027): Whether
CR Pharmaceutical Commercial’s accounts-receivable turnover (2.86xin FY2025) stabilizes as provincialNHSAdirect-settlement pilots expand alongside the January 1, 2027 implementation of the 2026NRDL.